Xiao Ma1, Jingjing Xu1, Jun Yang1. 1. Department of Respiration, Wuhu Traditional Chinese Medicine Hospital Wuhu 241000, Anhui Province, China.
Abstract
OBJECTIVE: To explore the efficacy of tiotropium bromide combined with different doses of fluticasone plus salmeterol DPI (dry powder for inhalation) in treating stable moderate to severe chronic obstructive pulmonary disease (COPD) and its influence on pulmonary function. METHODS: From August 2017 to November 2019, 105 patients with stable moderate to severe COPD in our hospital were enrolled and divided into three groups: group A (GA), group B (GB) and group C (GC). In GA, patients received tiotropium bromide combined with low dose of fluticasone plus salmeterol. In GB, patients received tiotropium bromide combined with medium dose of fluticasone plus salmeterol. In GC, patients received tiotropium bromide combined with high dose of fluticasone plus salmeterol. The baseline data and adverse reactions were observed in each group. After therapy, the improvement of clinical symptoms, quality of life, pulmonary function index and therapeutic effect were observed in each group. RESULTS: There was no difference in the general data of patients among the groups (P>0.05). The improvement of clinical symptoms in GB was better than that in GA, and that in GC was better than that in GB (P<0.05). There was no difference in adverse reactions among the groups (P>0.05). After treatment, IL-8, MPO, LTB4 and the number of inflammatory cells in sputum in the three groups decreased; the four in GB group were dramatically lower than those in GA group, and those in GC group were dramatically lower than those in GB group. The lung function indexes of patients in GB were better than those in GA, and those in GC were better than those in GB (P<0.05). The efficacy in GB was better than that in GA, and that in GC was better than that in GB (P<0.05). The quality of life scores in GB were higher than those in GA, and those in GC were higher than those in GB (P<0.05). CONCLUSION: Tiotropium bromide combined with high dose of salmeterol xinafoate (SX) and fluticasone propionate (FP) powder for inhalation can effectively improve the pulmonary function of patients with moderate to severe stable COPD. AJTR
OBJECTIVE: To explore the efficacy of tiotropium bromide combined with different doses of fluticasone plus salmeterol DPI (dry powder for inhalation) in treating stable moderate to severe chronic obstructive pulmonary disease (COPD) and its influence on pulmonary function. METHODS: From August 2017 to November 2019, 105 patients with stable moderate to severe COPD in our hospital were enrolled and divided into three groups: group A (GA), group B (GB) and group C (GC). In GA, patients received tiotropium bromide combined with low dose of fluticasone plus salmeterol. In GB, patients received tiotropium bromide combined with medium dose of fluticasone plus salmeterol. In GC, patients received tiotropium bromide combined with high dose of fluticasone plus salmeterol. The baseline data and adverse reactions were observed in each group. After therapy, the improvement of clinical symptoms, quality of life, pulmonary function index and therapeutic effect were observed in each group. RESULTS: There was no difference in the general data of patients among the groups (P>0.05). The improvement of clinical symptoms in GB was better than that in GA, and that in GC was better than that in GB (P<0.05). There was no difference in adverse reactions among the groups (P>0.05). After treatment, IL-8, MPO, LTB4 and the number of inflammatory cells in sputum in the three groups decreased; the four in GB group were dramatically lower than those in GA group, and those in GC group were dramatically lower than those in GB group. The lung function indexes of patients in GB were better than those in GA, and those in GC were better than those in GB (P<0.05). The efficacy in GB was better than that in GA, and that in GC was better than that in GB (P<0.05). The quality of life scores in GB were higher than those in GA, and those in GC were higher than those in GB (P<0.05). CONCLUSION: Tiotropium bromide combined with high dose of salmeterol xinafoate (SX) and fluticasone propionate (FP) powder for inhalation can effectively improve the pulmonary function of patients with moderate to severe stable COPD. AJTR
Authors: Jörg D Leuppi; Philipp Schuetz; Roland Bingisser; Michael Bodmer; Matthias Briel; Tilman Drescher; Ursula Duerring; Christoph Henzen; Yolanda Leibbrandt; Sabrina Maier; David Miedinger; Beat Müller; Andreas Scherr; Christian Schindler; Rolf Stoeckli; Sebastien Viatte; Christophe von Garnier; Michael Tamm; Jonas Rutishauser Journal: JAMA Date: 2013-06-05 Impact factor: 56.272
Authors: Gaetano Caramori; Paolo Casolari; Adam Barczyk; Andrew L Durham; Antonino Di Stefano; Ian Adcock Journal: Semin Immunopathol Date: 2016-05-13 Impact factor: 9.623